FEATURES OF STANDARDIZATION AND REGISTRATION OF DIETARY SUPPLEMENTS COMPARED TO DRUGS

O. Bevz, O. Kryvanych, A. Fedosov, I. Sych, L. Perekhoda

Both medicines with well-studied medical use and traditional finished pharmaceutical products (FPP) and dietary supplements (DS) are in the category of over-the-counter medications and are used at the stage of pre-care for symptomatic therapy and to improve the quality of life of the patient. State registration of medicinal products is regulated by a number of legislative acts, decrees, instructions and orders, while the registration of dietary supplements in the territory of Ukraine is equivalent to the registration of food supplements and is regulated only by a few legal documents. Therefore, there are a number of issues that still need to be addressed to improve the quality of DS and FPP in order to provide the population with effective and equivalent drugs.

According to the Order of the Ministry of Health of Ukraine No. 876, as of 2019, 2961 OTC drugs were registered in the State Register of Medicinal Products of
Ukraine, which is 129 points less than were registered in the previous year; most of the products removed from the register were included in dietary supplements. The most popular dietary supplements are vitamin or mineral supplements (43 %) followed by special supplements (20 %), herbal remedies (20 %) and sports nutrition (16 %) [2].

The current stage of development of the pharmaceutical market of Ukraine is characterized, on the one hand, by the increasing development of non-state forms of ownership, on the other - by the effective use of state regulation and control. For Ukraine, as in many countries in the world, the pharmaceutical market is a driving force for improving the health of the nation and a promising business area. Ukraine has all the conditions for the pharmaceutical market to develop and provide the population with high quality DS and FPP [3].

According to the Law of Ukraine "About Medicines", the term medicinal product includes substances or mixtures of natural, synthetic or biotechnological origin that are used to prevent pregnancy, prevention, diagnosis and treatment of human diseases or changes in the state and functions of the body. Medicinal products include active pharmaceutical ingredients (active substances), finished pharmaceutical products (medicines, drugs), homeopathic remedies, agents used to identify pathogens, and control of pathogens or parasites, medicinal cosmetics and dietary supplements to food.

Finished pharmaceutical products (medicines, drugs) - dosed drugs in the form and condition in which they are used, which have passed all stages of production (manufacture), including final packaging.

According to the Order of the Ministry of Health of Ukraine dated 19.12.2013 No. 1114 “On Approval of Hygienic Requirements for Dietary Supplements” in article I. In the general guidelines state – "Dietary supplements may contain a wide range of nutrients and other ingredients, including vitamins, minerals, amino acids, essential fatty acids, fiber, various herbs and herb extracts" [4]. However, unlike drugs, DS are available as a solid, solid or liquid dosage form for oral use only, and are intended for therapeutic nutrition, health promotion and as an additional component of diet [5].

There are a number of products that include the same components, but some are implemented as FPP and the other as DS. We faced with the question of comparing the features of DS standardization and certification versus FPP to determine the difference between their pharmacological action and biological equivalence.

3. Materials and methods
The basic legislative act regulating the quality control of drugs in Ukraine at all stages of production, sale, storage, etc. is the Law of Ukraine “On Medicines” [6], however, 41 legislative documents (laws, regulations, resolutions, acts) are presented on the website of the State Drug Service of Ukraine, relating to all stages of the life cycle of a drug, from synthesis, preclinical and clinical research, production to control and post-marketing research.

The document regulating the state registration / re-registration of medicinal products is the Decree of the Cabinet of Ministers of Ukraine “On approval of the procedure for state registration (re-registration) of medicinal products and the amount of fees for their state registration (re-registration)” [7].

Unlike drugs, the quality of dietary supplements is regulated by food law [8]: the Law of Ukraine “On Basic Principles and Requirements for Food Safety and Quality”, the Law of Ukraine “On Consumer Information on Foodstuffs, the Order”, “On Approval of the Regulation on Food the State Sanitary and Epidemiological Service of the Security Service of Ukraine”, the Decree of the Ministry of Health of Ukraine on “Hygienic Requirements for Dietary Supplements”, and the Law of Ukraine “About Food Information For Consumers”.

The main regulatory act under which the quality of drugs is controlled is the State Pharmacopoeia of Ukraine (SPhU), and the second edition includes a general article “Dietary Supplements”, which is informative for quality control and components of DS [9, 10].

4. Results of the research
Dietary supplements are implemented through a multi-level marketing system or via the Internet and post, that’s why it is virtually impossible to control product quality. According to the analysis of the legislative framework, legislation on the basic principles and requirements for food safety and quality (including DS) on the territory of Ukraine is in force, which manufacturers and distributors must follow during implementation, but there are no requirements and regulatory documents (quality control methods, standardized quality assurance techniques, etc.) for quality control ready for DS implementation [11].

Analysis of DS safety data showed that [12, 13]:
- they may contain highly active substances or no biologically active components at all;
- the information material does not provide complete information on the quantitative composition of all ingredients, including excipients;
- administration contraindications are often absence;
- no DS interaction data with drugs;
- in most cases there is no indication of the safety of use in pregnant women, the fetus and breastfeeding;
- there is no clear evidence of their effectiveness when used as proposed.

In 2010, the Concept of Development of the Ukrainian Healthcare Pharmaceutical Sector for 2011–2020 was approved, which defines measures based on which the efficiency and effectiveness of standards are ensured, requirements for each link of medicinal prod-
The main objectives of the Concept are to determine the strategy of the pharmaceutical sector, which should ensure the proper level of quality and effectiveness of pharmacotherapy, promote health, increase life expectancy and quality of life of the entire population of Ukraine. However, in this concept nothing is mentioned about DS, although their number in pharmacy chains is increasing every day, for example, part of the vitamin, bacterial drugs, etc., in most countries of the world referred to DS. They are manufactured, including at pharmaceutical manufactures of Ukraine, and the requirements for them differ from the requirements for drugs [13, 14].

One of the indicators of quality is the efficacy and safety that is validated for pre-clinical and clinical trials for medicinal products, but as noted above, DS includes components that have an evidence base and are approved for use. The features of determining the efficacy and safety of drugs and DS in accordance with the current legislation of Ukraine were summarized and presented in Fig. 1.

After validation and establishment of efficiency and safety, quality control (QA), which should occur at all stages from synthesis, process, production, registration and control of finished products, is no less important.

QA of drugs in Ukraine are carried out in accordance with the requirements (monographs) of SPbU, international ISO standards and ICH guidelines, but the requirements for DS QA are made only in the general SPbU article and applicable regulations.

The methods proposed for QA of drugs must be accurate, sensitive, highly reproducible, i.e. validated or verified [15]. In order to prevent errors, calibrated and qualified utensils and equipment shall be used for testing and shall be carried out in premises meeting certain requirements [16–20].

The general data given in the current legislation of Ukraine regarding the quality requirements of DS compared to FPP, which must be checked during the QA are shown in Fig. 2.

<table>
<thead>
<tr>
<th>Finished pharmaceutical products</th>
<th>Indicator</th>
<th>Dietary supplements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depending on the pharmacological properties of the active pharmaceutical ingredients, age and condition of the patient</td>
<td>Dosage</td>
<td>The daily doses of consumption are approved by the Chief Sanitary Doctor of Ukraine, according to the legislation</td>
</tr>
<tr>
<td>It is determined by pharmacological properties</td>
<td>Efficiency</td>
<td>Determined on the basis of the source of the action of the ingredients or information on the authorization of the use of a particular additive, component or ingredient</td>
</tr>
<tr>
<td>Complex of toxicological and biomedical studies at all stages of the life cycle</td>
<td>Safety</td>
<td>Used according to the instructions, the dose-response relationship is not determined experimentally</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dosage form, depending on the route of administration (parenteral, sublingual, oral, etc.)</td>
<td>Input path and dosage form</td>
<td>Solid, soft or liquid oral dosage forms</td>
</tr>
</tbody>
</table>

Fig. 1. Determining the effectiveness and safety of drugs and DS
Pharmaceutical drugs | Dietary supplements
---|---
Appropriate methods, should be:  
- Specificity;  
- Accuracy;  
- Reproducibility  
Identification  
The content of heavy metals (maximum levels, mg / kg): lead - 3.0, cadmium - 1.0 (DS, produced from marine organisms - 3.0), mercury - 0.1 [17]

Determination of impurities with their limits [18, 19]:  
- organic / inorganic/solvents,  
- known / potential,  
- specific / non-specific  
Tests  
- “Microbial limit test”  
- “Dissolution” for pharmaceutical drugs  
- “Uniformity of dosage units” for pharmaceutical drugs  
- Residual pesticides  
- Aflatoxins
  
Methods of quantitative determination of APIs and excipients, which proved [20]:  
- Correctness (accuracy);  
- Precision (convergence);  
- Specificity;  
- Linearity;  
- Detection limit range  
Assay  
Carry out a quantitative determination by similar methods for individual groups of active ingredients

Fig. 2. Indicators that are taken into account when developing FPP and DS quality control techniques

The DS safety and quality profile is used to protect the life and health of the population from the harmful factors that may be present in DS components [21]. In terms of FPP quality, efficiency and safety, it is a complete set of measures that control the whole “life cycle” from production to the expiration date of all indicators (identification, purity, quantification and release of the active substance).

5. Discussion of the results
In accordance with the requirements for efficiency and safety, as well as the indicators taken into account in the standardization of quality control procedures, registration takes place for DS and FPP by different organizations and by different procedures.

The Ukrainian legislation on state registration of medicinal products has in most respects been brought into line with EU law. Given that FPPs are exported to other countries of the world, or imported FPPs are undergoing the necessary registration procedure in Ukraine, the requirements for pharmaceutical products must comply with global standards regarding the requirements for components, process and conditions of manufacture, quality, safety and efficiency testing, and packaging mark [22]. To register FPP, you must submit an application to the Ministry of Health of Ukraine, to which is added a dossier consisting of five modules, including materials of preclinical, clinical study, process description and quality control methods, with the submission of validation or verification procedure documents. A prerequisite is that each FPP creation and implementation process is relevant to good pharmaceutical practices; report on evaluation of the EMA registration dossier and corresponding conclusion of the State Expert Centre of the Ministry of Health of Ukraine (Fig. 3) [23].
In turn, the DS registration process takes less time and paperwork. Only the application for the sanitary and epidemiological examination, the samples of the object, the recommendations for application and the instruction, as well as the specification indicating the DS components and their identification indicators are required. Documents certifying safety and quality, regulatory and veterinary approvals for products of animal origin shall also be added if available [24].

The procedure for DS registration in the territory of Ukraine according to the requirements of the Ministry of Health can be provided as follows (Fig. 4).

Thus, the Ministry of Health of Ukraine issues a registration certificate for the medicinal product, and the State Service of Ukraine for Food Safety and Consumer Protection issues a conclusion of the state sanitary-expert examination, and in the presence of these documents the supplements are allowed for sale. However, the DS registration procedure is flawed, no documents are provided to confirm the quantitative content of the constituents in the composition, and the effects of the excipients or combination of ingredients are not verified in terms of pharmacological action and safety.

The question of dietary supplements that can be purchased via the Internet from abroad remains open, given that the turnover of these DS is not subject to state control.
6. Conclusions

The rapid increase in the production and import/export of DS and OTC FPPs has led to a revision of current Ukrainian legislation and the need to harmonize requirements with the EU. All this is a prerequisite for the need to fully carry out biomedical evaluation, control of registration and the creation of a proper regulatory framework that would ensure the quality and safety of DS for consumers, given that both the composition and dosage of such products are now practically without expert evaluation.

References


17. Pro zatverdzhennia Derzhavnikh hiihienichnych pravyl i norm "Rehlament maksymalnykh rivniv okremykh zabrudnuiuchychkh rechovyn u kharchovykh produkttakh" (2013). Nakaz MOZ Ukrainy No. 368. 13.05.2013. Available at: https://zakon.rada.gov.ua/laws/show/z0774-13


Received date 15.10.2019
Accepted date 17.11.2019
Published date 30.12.2019

Olena Bevz, PhD, Assistant, Department of Medicinal Chemistry, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: bevz.helen@gmail.com

Olga Kryvanych, PhD, Associate Professor, Department of Pharmaceutical Disciplines, Uzhhorod National University. Narodna sq., 3, Uzhhorod, Ukraine, 88000
E-mail: oglabezv87@gmail.com

Andrii Fedosov, Doctor of Pharmaceutical Sciences, Associate Professor, Chief Vice-Rector on Educational Work, Department of Medicinal Chemistry, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: prorector1@nuph.edu.ua

Irina Sych, PhD, Associate Professor, Department of Medicinal Chemistry, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine 61002
E-mail: irina777sych@gmail.com

Lina Perekhoda, Doctor of Pharmaceutical Sciences, Professor, Head of Department, Department of Medicinal Chemistry, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: linaperekhoda@ukr.net